, also known as or D-Deprenyl , is an dextro- N-propargyl- N-methylamphetamine MAO-B inhibitor that metabolizes into and D-amphetamine and is therefore also a D-methamphetamine norepinephrine-dopamine releasing agent.     It is the opposite  enantiomer of (selegiline). L-deprenyl
L-Deprenyl, also an MAO-B inhibitor, metabolizes to and L-amphetamine , which are both L-methamphetamine norepinephrine releasing agents. In contrast, D-deprenyl additionally has dopaminergic effects and has been found to be reinforcing in scientific research, whereas L-deprenyl is not known to have any appreciable psychological reinforcement.  
In addition to its actions as an MAO-B inhibitor and NDRA,
D-deprenyl has been found to bind with high affinity to the σ (K 1 receptor i = 79 nM) similarly to various other amphetamine derivatives.  Its  L-isomer, selegiline, binds with 3.5-fold lower affinity in comparison.  
See also [edit ]
References [edit ]
^ C Thiffault; R Quirion; J Poirier (October 1997). "The effect of l-deprenyl, d-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity". Molecular Brain Research. 49 (1–2): 127–136. doi: 10.1016/S0169-328X(97)00135-6. PMID 9387872.
^ Srinivasan ThyagaRajan; Kelley S. Madden; Gary W. Boehm; Suzanne Y. Stevens; David L. Felten; Denise L. Bellinger (January 2013). "l-Deprenyl Reverses Age-Associated Decline in Splenic Norepinephrine, Interleukin-2 and Interferon-γ Production in Old Female F344 Rats". Neuroimmunomodulation. 20 (2): 72–78. doi: 10.1159/00034504. PMC 3695399 . PMID 23207416.
^ Dhanasekharan Muralikrishnan; Supriti Samantaray; Kochupurackal P. Mohanakumar (October 2003). "D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity". Synapse. 50 (1): 7–13. doi: 10.1002/syn.10239. PMID 12872288.
^ László Simon; Géza Szilágyi; Zoltán Bori; Péter Orbay; Zoltán Nagy (November 2001). "(−)-d-Deprenyl attenuates apoptosis in experimental brain ischaemia". European Journal of Pharmacology. 430 (2–3): 235–241. doi: 10.1016/S0014-2999(01)01375-9. PMID 11711036.
^ S Yasar; C W Schindler; E B Thorndike; I Szelenyi; S R Goldberg (April 1993). "Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats.". Journal of Pharmacology and Experimental Therapeutics. 265 (1): 1–6. PMID 8473997.
^ Yasar S; Gaál J; Panlilio LV; et al. (January 2006). "A comparison of drug-seeking behavior maintained by d-amphetamine, l-deprenyl (selegiline) and d-deprenyl under a second-order schedule in squirrel monkeys". Psychopharmacology. 183 (4): 413–21. doi: 10.1007/s00213-005-0200-7. PMC 1360227 . PMID 16292593.
^ Winger GD, Yasar S, Negus SS, Goldberg SR (December 1994). "Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys". Clinical Pharmacology & Therapeutics. 56 (6): 774–780. doi: 10.1038/clpt.1994.208. PMID 7995020.
^ a b Yossef Itzhak (1994). . Academic Press. p. 84. Sigma Receptors ISBN 978-0-12-376350-1.
^ a b T. W. Stone (January 1993). . Taylor & Francis. pp. 124–. Acetylcholine, Sigma Receptors, CCK and Eicosanoids, Neurotoxins ISBN 978-0-7484-0063-8.